卢马特佩龙用于治疗具有混合特征的严重抑郁症或具有混合特征的双极抑郁症:一个随机的安慰剂控制试验
Suresh Durgam1, Susan G Kozauer1, Willie R Earley1
1From Intra-Cellular Therapies, Inc., Bedminster, NJ.
Journal of clinical psychopharmacology
|February 13, 2025
概括
卢马特在患有严重抑郁症 (MDD) 或双极抑郁症和混合特征的患者中显著改善了抑郁症症状. 治疗被发现是安全的,耐受性很好,没有增加躁狂风险.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在严重抑郁症 (MDD) 和双相情感障碍中出现重度抑郁发作 (MDE) 和具有混合特征的双相情感障碍,代表着大量未满足的医疗需求.
- 评估这些复杂情绪障碍的新型治疗方案至关重要.
研究的目的:
- 评估lumateperone在治疗与MDD或双相特征双极障碍相关的MDE的疗效和安全性.
- 在一项随机,双盲,受控试验中,将42毫克的卢马特佩龙与安慰剂进行比较.
主要方法:
- 一项随机,双盲,安慰剂对照试验 (NCT04285515) 涉及385名患有多发性精神障碍的患者 (185名患有多发性精神障碍,200名患有双相情感障碍).
- 参与者被随机分配1:1接受安慰剂或42毫克卢马特佩龙6周.
- 主要和次要终点测量了使用蒙哥马利-阿斯伯格抑郁症评分表 (MADRS) 和临床全球印象表-严重性 (CGI-S) 的抑郁症和严重性得分的变化.
主要成果:
- 与安慰剂相比,卢马特佩龙显著改善了MADRS总得分,在MDD/双极性抑郁症组合,MDD-only和双极性抑郁症-only人群中显著改善 (P < 0.0001).
- 在CGI-S和Young Mania评分表得分上也观察到与lumateperone的显著改善.
- 卢马特佩龙耐受性良好,常见的不良事件包括昏昏欲睡和头;没有发现躁狂或显著代谢问题的风险增加.
结论:
- 卢马特佩龙42毫克在减少MDD或双极性抑郁症患者的抑郁症状和疾病严重程度方面表现出显著的有效性.
- 卢马特佩龙的安全性概况是有利的,耐受性很好,没有出现躁狂/低躁狂.
- 卢马特为患有混合特征抑郁症的患者提供了一个有前途的治疗选择.
更多相关视频
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
01:24Mania and Antimanic Drugs: Overview
117
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
117
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
285
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
285
01:23Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183
01:30Bipolar Disorder
46
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
46
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22